Showing results (81-90 of 103) with videos related to

Sort By:
Pageof 11
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 12, 2026
Clinical experience and satisfaction in patients with advanced breast cancer participating in the abemaciclib patient support program in Spain: a prospective observational studyIsabel Blancas, Miriam González de la Peña, María Fernández Abad, et al.
JNCI Cancer Spectrum|August 12, 2025
Comparative efficacy between real-world and randomized studies of palbociclib+endocrine therapy in HR-positive/HER2-negative metastatic breast cancer: systematic review and meta-analysisFrancesco Schettini, Sabrina Nucera, Giuseppe Di Grazia, et al.
Cancer Treatment Reviews|December 22, 2024
Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysisFrancesco Schettini, Sabrina Nucera, Tomás Pascual, et al.
NPJ Precision Oncology|November 7, 2025
Co-clinical trial targeting ER, FGFR and CDK4/6 in resistant hormone-positive breast cancer with FGFR alterationsNoelia Martinez-Jañez, José Ángel García-Saenz, Sonia Pernas, et al.
Cytokine|February 19, 2021
Characterization of the perioperative changes of exosomal immune-related cytokines induced by prostatectomy in early-stage prostate cancer patientsMónica Macías, Ángel García-Cortés, Marcos Torres, et al.
Breast Cancer Research and Treatment|May 4, 2024
Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2- advanced breast cancer: a real-world evidence cohortRodrigo Sánchez-Bayona, Alfonso Lopez de Sa, Yolanda Jerez Gilarranz, et al.
JPEN. Journal of Parenteral and Enteral Nutrition|October 5, 2024
Short bowel syndrome related intestinal failure outcomes in Latin America: Insights from the RESTORE RegistryCarolina Rumbo, Hector Solar, Mariana Ortega, et al.
European Journal of Cancer (Oxford, England : 1990)|January 8, 2025
Efficacy outcomes of CDK4/6 inhibitors in combination with endocrine therapy treatment in hormone receptor-positive/HER2-negative advanced breast cancer according to PAM50 intrinsic subtype: Primary results of SOLTI-1801 CDK-PREDICT studyPablo Tolosa, Tomás Pascual, Olga Martínez-Saez, et al.
Translational Lung Cancer Research|April 23, 2021
Whole exome sequencing characterization of individuals presenting extreme phenotypes of high and low risk of developing tobacco-induced lung adenocarcinomaAna Patiño-García, Elizabeth Guruceaga, Victor Segura, et al.
Breast (Edinburgh, Scotland)|July 18, 2026
Latin American consensus on the medical oncologic management of early-stage HR+/HER2- breast cancer: Addressing regional disparities in Spanish-speaking countriesDenis U Landaverde, Fernando Petracci, Angela Grano de Oro, et al.
Pageof 11